Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and ... Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications. 더 보기
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.39 | 8.36909871245 | 4.66 | 5.15 | 4.05 | 236486 | 4.85573191 | CS |
4 | 0.95 | 23.1707317073 | 4.1 | 5.5 | 3.8113 | 223979 | 4.65200203 | CS |
12 | 0.11 | 2.22672064777 | 4.94 | 7.2 | 2.92 | 345050 | 5.15449191 | CS |
26 | -1.5 | -22.9007633588 | 6.55 | 7.93 | 2.92 | 296544 | 5.17110626 | CS |
52 | -1.5 | -22.9007633588 | 6.55 | 7.93 | 2.92 | 296544 | 5.17110626 | CS |
156 | -1.5 | -22.9007633588 | 6.55 | 7.93 | 2.92 | 296544 | 5.17110626 | CS |
260 | -1.5 | -22.9007633588 | 6.55 | 7.93 | 2.92 | 296544 | 5.17110626 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관